Armata achieved a major milestone with positive topline results from its Phase 1b/2a clinical trial of AP-SA02 for Staphylococcus aureus bacteremia. These 10 stocks could mint the next wave of ...

New data shows Recce's topical gel is highly effective against two challenging antibiotic-resistant bacteria affecting burns.

CMTX-101 is an investigational immune-enabling antibody designed to target and destroy the pro-inflammatory structure of bacteria biofilms.

The FDA has granted Fast Track and QIPD designations to CMTX-101 for the treatment of CF in patients affected by chronic bacterial pulmonary infections.

An update from Armata Pharmaceuticals ( ($ARMP) ) is now available. On August 11, 2025, Armata Pharmaceuticals entered into a secured credit ...

Advancement of modular therapies offers a new dynamic for today’s patients, but there’s still a need to maintain infection ...

Contact lenses are preferred for convenience, but this should not compromise maintaining adequate precautions; otherwise, ...

A 56-year-old woman with a history of relapsed/refractory IgG kappa multiple myeloma presented with a 3-day history of right ...

A FRESH bombshell theory in Lucy Letby’s case is a “smoking gun” that casts even MORE doubt over the killer nurse’s convictions, medical experts say. After two ...

Copenhagen-based SNIPR Biome, a biotech company focused on developing precision medicines through CRISPR technology for ...

Shares reset record before the RBA’s rate call; South Australian regulator says SkyCity has shortcomings; SGH dumped despite ...

SNIPR Biome ApS (“SNIPR”), the company pioneering the development of microbial CRISPR-medicine, today announced the close of a EUR 35 million Series B raise with funding from new investors the Cystic ...